CompletedPhase 3NCT02085408
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Studying Acute erythroid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Principal Investigator
- James ForanEastern Cooperative Oncology Group
- Intervention
- Daunorubicin(drug)
- Enrollment
- 727 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2011 – 2022
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Arizona Cancer Center at University Medical Center North, Tucson, Arizona, United States
- University of Arizona Health Sciences Center, Tucson, Arizona, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Saint Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Exempla Saint Joseph Hospital, Denver, Colorado, United States
- Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Colorado Cancer Research Program CCOP, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02085408 on ClinicalTrials.govOther trials for Acute erythroid leukemia
Additional recruiting or active studies for the same condition.